ClinicalTrials.gg
TerminatedNCT05529316Updated Oct 19, 2026

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

A Phase 2 interventional study of Botensilimab and Balstilimab in Advanced Melanoma, sponsored by Agenus Inc.. Terminated at 51 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Agenus Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision
Updated Oct 19, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 70 under way, 20 of them phase 3. Melanoma · Germany.

Enrollment
130th of 249
150 · median 162
Started
2022
with 16 others
Phase 2
80 of 284
6 open now
Registered
239th of 284
by date

Among the 284 studies in Melanoma with a site in Germany, this one is the 130th largest by enrollment of the 249 interventional ones that give a count, is one of 17 that started in 2022, is one of 80 in phase 2, and was the 239th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Melanoma with a site in Germany, or all of them as a file.
02

Study summary

This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy.

Read the detailed description

This Phase 2 study will enroll up to approximately 220 evaluable adult participants with a histologically confirmed diagnosis of either Stage III (unresectable) or Stage IV cutaneous melanoma and who have had prior treatments with anti-programmed death (ligand) 1 [PD-(L)1].

This study will consist of 2 parts. Part 1 consists of 2 cohorts (Cohorts A and B) that will receive botensilimab monotherapy. In Cohort A, participants refractory to PD-(L)1 will receive botensilimab. In Cohort B, participants refractory to PD-(L)1 and cytotoxic T-lymphocyte antigen 4 (CTLA-4) will receive botensilimab. Part 2 consists of Cohorts A and B that will receive botensilimab combination therapy. In Cohort A, participants refractory to PD-(L)1 will receive botensilimab in combination with balstilimab. In Cohort B, participants refractory to PD-(L)1 and CTLA-4 will receive botensilimab in combination with balstilimab.

03

Conditions studied

  • Advanced Melanoma

Browse trials for

Keywords

  • Open-label
  • Monotherapy
  • Combination Therapy
  • Anti-PD-1
  • Anti-PD-L1
  • Anti-CTLA-4
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To participate in the study, participants must meet all the following inclusion criteria:

Cohort A only:

  1. Prior treatment with anti-PD-(L)1 therapy (for example, pembrolizumab or nivolumab) for at least 6 weeks and radiologic progression confirmed by 2 scans at least 4 weeks apart, or if symptomatic due to progressive , then 1 scan showing progression is sufficient.
  2. Progression must be either on treatment with anti-PD-(L)1 regimen or ≤ 12 weeks from last anti-PD-(L)1 dose in setting or ≤ 24 weeks from completion of therapy in / neoadjuvant setting.
  3. For Part 2 only, no intervening anti-cancer therapy between the last course of anti-PD-(L)1 treatment and the first dose of study treatment except for local measures (for example, surgical excision, , focal radiation therapy), or BRAF ± MEK inhibition when applicable in BRAF mutant participants.

Cohort B only:

  1. Prior treatment with first-generation therapy (for example, ipilimumab or tremelimumab) and prior treatment with anti-PD-(L)1 for at least 6 weeks.
  2. Progression on most recent anti-cancer therapy.
  3. For Part 2 only, no more than 3 in the advanced setting for BRAF mutant and no more than 2 prior lines of therapy in the advanced setting in the BRAF wild type.

Cohorts A and B:

  1. Voluntarily agree to participate by giving signed, dated, and written prior to any study-specific procedures.
  2. confirmed Stage III (unresectable) or Stage IV histologically confirmed cutaneous melanoma as per the American Joint Committee on Cancer 8th edition staging system.
  3. on baseline imaging per 1.1 criteria.
  4. BRAF V600 mutation status or consent to BRAF V600 mutation testing per local institutional standards during the screening period.
  5. ≥ 3 months.
  6. performance status of 0 or 1.
  7. Adequate organ function is defined as the following laboratory values within 14 days of Cycle 1 Day 1 (C1D1):

    1. Neutrophils > 1500/microliter (μL) (stable off any growth factor within 4 weeks of first study treatment administration).
    2. > 100 × 10\^3/μL (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration).
    3. > 8.0 grams/deciliter (g/dL) (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration).
    4. ≥ 45 milliliters/minute (measured or calculated using modification of diet in renal disease).
    5. /alanine aminotransferase \< 3.0 × (ULN).
    6. Total \< 1.5 × ULN, or \< 3.0 × ULN for participants with Gilbert syndrome.
    7. Albumin ≥ 3.0 g/dL.
    8. or prothrombin time ≤ 1.5 × ULN and activated partial thromboplastin time ≤ 1.5 × ULN (unless participant is receiving anticoagulant therapy).
  8. Participant must provide a formalin-fixed paraffin-embedded tumor tissue sample from the most recent biopsy of a tumor lesion, obtained within 90 days from signing informed consent form. If recent tumor tissue is unavailable or inadequate, a fresh biopsy will be required, unless the Sponsor agrees that it is not safe/feasible.
  9. Women of (WOCBP) must have a negative urine or serum pregnancy test at screening (within 72 hours of first dose of study medication) and prior to study drug administration. In part 1, WOCBP must agree to use highly effective measures starting with the screening visit through 3 months after the last dose of study treatment. In Part 2, WOCBP must agree to use highly effective contraceptive measures starting with the screening visit through 5 months after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the participant.
  10. In Part 1, male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study, starting with the screening visit through 3 months after the last dose of study treatment is received. In Part 2, male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 5 months after the last dose of study treatment is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

Exclusion criteria

Exclusion Criteria:

To participate in the study, participants must meet none of the following exclusion criteria:

Cohort A:

1. Received prior therapy.

Cohort B:

1. Received prior Fc-engineered or Fc-enhanced anti-CTLA-4 therapy (for example, BMS-96218, BMS-986288, HBM4003, XTX101, CTLA-4 targeting bispecific or other approaches such as ONC-392).

Cohorts A and B:

  1. Ocular, uveal, or mucosal melanoma.
  2. Any persistent toxicities ( [CTCAE] Grade ≥ 2) from prior cancer therapy, excluding endocrinopathies stable on medication, stable neuropathy, and alopecia.
  3. Any history of CTCAE Grade ≥ 3 immune-mediated toxicity (excluding endocrinopathies and non-necrotizing/bullous rash) from prior checkpoint inhibitor therapy that required treatment with systemic (> 10 mg/day prednisone or equivalent) or other medications for more than 4 weeks.
  4. ascites require 2 or more therapeutic paracentesis in the last 4 weeks or ≥ 4 within the last 90 days prior to study entry.
  5. Bowel obstruction within the past 3 months or an impending bowel obstruction.
  6. (that is, active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure ( class ≥ III), or serious uncontrolled cardiac arrhythmia requiring medication.
  7. Active or with the following exceptions:

    1. Treated brain metastases require a) surgical resection, or b) stereotactic radiosurgery. These participants must be off steroids ≥ 10 days prior to randomization for the purpose of managing their brain metastases. Repeat brain imaging following surgical resection or stereotactic radiosurgery is not required if their last brain magnetic resonance imaging is within screening window. Whole-brain radiation is not allowed.
    2. Untreated isolated brain metastases that are too small for treatment by surgical resection or stereotactic radiosurgery (for example, 1-2 millimeters) and/or of uncertain etiology are potentially eligible but need to be discussed with and approved by the study Medical Monitor.
  8. Concurrent (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment (that is, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before the first dose of study treatment and the participant has no evidence of disease). Participants with history of prior early-stage basal/squamous cell skin cancer, low-risk prostate cancer eligible for active surveillance or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible.
  9. Incomplete resolution of clinically significant adverse events related to most recent therapy/intervention prior to enrollment.
  10. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine or booster \< 7 days before C1D1. For vaccines requiring more than 1 dose, the full series should be completed prior to C1D1, when feasible. A booster shot is not required but if given, must be administered > 7 days from C1D1 or > 7 days from future cycle on study.
  11. Known allergy or to any of the study drugs or any of the study drug .
  12. Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring high-dose glucocorticoids.
  13. History of allogeneic organ transplant, stem cell transplant or bone marrow transplant ( stem cell transplant > 5 years prior to study enrollment with no evidence of disease are eligible unless lymphopenia Grade > 1 is present).
  14. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
  15. Participants with a condition requiring systemic treatment with either corticosteroids (> 10 milligrams [mg] daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active disease.
  16. Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years before starting study treatment (that is, with use of disease-modifying agents or immunosuppressive drugs).
  17. History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the participants participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
  18. A who is pregnant or breastfeeding or WOCBP who are not willing to employ effective from screening to 90 days after the last dose of botensilimab (whichever is later).
  19. Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1.
  20. Uncontrolled infection with (HIV). Participants on stable highly active antiretroviral therapy with undetectable viral load and normal cluster of differentiation 4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required.
  21. Known to be positive for virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Participants who are receiving or who have received anti-HBV therapy and have undetectable HBV DNA for at least 6 months prior to study entry are eligible. Serological testing for HBV at screening is not required.
  22. Known active virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Participants on or who have received antiretroviral therapy are eligible, provided they are virus-free by PCR for at least 6 months prior to study entry. Serological testing for HCV at screening is not required.
  23. Dependence on total parenteral nutrition.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Part 1 Cohort A: Botensilimab

    Participants refractory to PD-(L)1 therapy will receive botensilimab intravenously (IV).

    Drug: Botensilimab

  • Experimental
    Part 1 Cohort B: Botensilimab

    Participants refractory to PD-(L)1 and anti-CTLA-4 therapies will receive botensilimab IV.

    Drug: Botensilimab

  • Experimental
    Part 2 Cohort A: Botensilimab + Balstilimab

    Participants refractory to PD-(L)1 will receive botensilimab IV in combination with balstilimab IV.

    Drug: Botensilimab · Drug: Balstilimab

  • Experimental
    Part 2 Cohort B: Botensilimab + Balstilimab

    Participants refractory to PD-(L)1 and CTLA-4 will receive botensilimab IV in combination with balstilimab IV.

    Drug: Botensilimab · Drug: Balstilimab

Interventions

  • An anti-CTLA-4 monoclonal antibody

    Also known as: AGEN1181

  • An anti-PD-1 monoclonal antibody

    Also known as: AGEN2034

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective response rate will be determined using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

    Time frame: Up to 40 months

Secondary outcomes

  1. Progression-free Survival

    Progression-free survival will be determined using RECIST 1.1.

    Time frame: From first dose to first observation of documented disease progression (or death within 12 weeks of last tumor assessment) (up to 3 months)

  2. Duration Of Response

    Duration of response will be determined using RECIST 1.1.

    Time frame: From first dose to first observation of documented disease progression (or death within 12 weeks of last tumor assessment) (up to 3 months)

  3. Overall Survival Time

    Overall survival will be quantified as a median.

    Time frame: First dose through up to 3 months

  4. Frequency of Treatment-emergent Adverse Events

    Time frame: First dose through up to 27 months

07

Study locations

51 sites
  • Scottsdale Healthcare Hospitals DBA HonorHealth
    Scottsdale, Arizona 85258, United States
  • Virginia K. Crosson Cancer Center at St. Jude Medical Center
    Fullerton, California 92835, United States
  • Providence Saint John's Health Center
    Santa Monica, California 90404, United States
  • Yale University School of Medicine - Yale Cancer Center
    New Haven, Connecticut 06520-8028, United States
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20057, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Universitair Ziekenhuis Brussel
    Jette, 1090, Belgium
  • Oncosite - Centro de Pesquisa Clinica Em Oncologia
    Ijuí, 98700-000, Brazil
  • Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho
    Jaú, 17210-080, Brazil
  • Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa
    Porto Alegre, 90110-270, Brazil
  • INCA II - Instituto Nacional de Cancer Jose Alencar Gomes da Silva
    Rio de Janeiro, 20220-410, Brazil
  • Hospital Sirio Libanes
    São Paulo, 01308-050, Brazil
  • Real e Benemerita Associaçao Portuguesa de Beneficencia - A Beneficencia Portuguesa de Sao Paulo
    São Paulo, 01323-001, Brazil
  • Hospital A.C. Camargo Cancer Center
    São Paulo, 01509-010, Brazil
  • CHU Amiens Picardie - Hopital Sud
    Amiens, 80054, France
  • CHU Grenoble-Alpes - Hopital Michallon
    La Tronche, 38700, France
  • Centre Leon Berard
    Lyon, 69008, France
  • CHU de Nantes
    Nantes, 44093, France
  • AP-HP Hopital Saint-Louis
    Paris, 75010, France
  • Centre Eugene Marquis
    Rennes, 35042, France
  • Gustave Roussy
    Villejuif, France
  • Universitaetsklinikum Essen
    Essen, 45122, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • University Hospital Schleswig-Holstein
    Kiel, 24105, Germany
  • Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz
    Mainz, 55131, Germany
  • Klinikum der Universitaet München
    München, 80377, Germany
  • Universitaetsklinikum Tuebingen
    Tübingen, 72076, Germany
  • Universitaetsklinikum Würzburg
    Würzburg, 97080, Germany
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
    Meldola, 47014, Italy
  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
    Naples, 80131, Italy
  • Azienda Ospedaliero Universitaria Senese
    Siena, 53100, Italy
  • Blokhin National Medical Research Oncology Centre
    Moscow, 115478, Russia
  • Branch Office of "Hadassah Medical Ltd"
    Moscow, 121205, Russia
  • Moscow City Oncology Hospital #62
    Moscow, 143423, Russia
  • LLC Medical Services
    Saint Petersburg, 194356, Russia
  • Clinical Hospital Russian Railways - Medicine
    Saint Petersburg, 195271, Russia
  • Petrov National Medical Research Center of Oncology
    Saint Petersburg, 197758, Russia
  • Hospital Universitario Vall d'Hebron
    Barcelona, 8035, Spain
  • Hospital Clinic Barcelona
    Barcelona, 8036, Spain
  • Onkologikoa
    Donostia / San Sebastian, 20014, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
  • Consorcio Hospital General Universitario de Valencia
    Valencia, 46014, Spain
  • CHUV - Centre hospitalier universitaire vaudois
    Lausanne, 1011, Switzerland
  • Universitaetsspital Zuerich
    Zurich, CH-8091, Switzerland
  • Royal Marsden Foundation Trust
    London, SW3 6JJ, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Mount Vernon Cancer Centre
    Middlesex, HA6 2RN, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2022 to primary completion in Apr 2026, 40 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Feb 2028 → Apr 2026 and completion Feb 2028 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2022
First posted
Sep 7, 2022
StartActual
Dec 12, 2022
Primary completionActual
Apr 27, 2026was Feb 2028
CompletionActual
Apr 27, 2026was Feb 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Sponsor decision
changed Oct 19, 2026
Primary completion
Feb 2028→Apr 27, 2026 (actual)
Oct 19, 2026
Study completion
Feb 2028→Apr 27, 2026 (actual)
Oct 19, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameObjective Response RateFirst dose through up to 3 months → Up to 40 months
Oct 19, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameFrequency of Treatment-emergent Adverse EventsFirst dose through up to 3 months → First dose through up to 27 months
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Terminated
    Why stopped Sponsor decision
    Primary completion Feb 2028→Apr 27, 2026 (now actual)
    Study completion Feb 2028→Apr 27, 2026 (now actual)
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameObjective Response RateFirst dose through up to 3 months → Up to 40 months
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameFrequency of Treatment-emergent Adverse EventsFirst dose through up to 3 months → First dose through up to 27 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05529316
Lead sponsor
Agenus Inc.
Responsible party
Sponsor
First posted
Sep 7, 2022
Start date
Dec 12, 2022
Primary completion
Apr 27, 2026
Completion
Apr 27, 2026
Last update
Oct 19, 2026

Study contacts

Medical Director
study director · Agenus Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botensilimab

Start the discussion